<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00716950</url>
  </required_header>
  <id_info>
    <org_study_id>UNIPV004DIM2008</org_study_id>
    <nct_id>NCT00716950</nct_id>
  </id_info>
  <brief_title>Valsartan and Amlodipine Compared to Losartan and Amlodipine in Hypertensive Patients</brief_title>
  <official_title>Evaluation of Antihypertensive Activity of Valsartan and Amlodipine Compared to Losartan and Amlodipine Through Ambulatory Blood Pressure Monitoring in Moderate Hypertensive Patients in a Randomized, Controlled, Double-Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pavia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertensive patients with moderate hypertension have a risk to develop cardiovascular events
      of 15-20% over a period of 10 years. It is important to reach quickly the advised target, but
      often this result can be obtained with a combination therapy. Some evidences demonstrate
      sartans and calcium channels blockers can be very useful and safe, but it is also important
      to verify which association can give side effects or give some pharmacokinetic interactions
      that can negatively influence the clinical combination efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">February 2009</completion_date>
  <primary_completion_date type="Anticipated">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 hours mean, determinated through ABPM; diastolic mean after 4 weeks of losartan 100mg/amlodipine 5mg and valsartan 160mg/amlodipine 5mg treatment</measure>
    <time_frame>after 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 hours systolic mean, determinated through ABPM; day systolic and diastolic mean determinated through ABPM; night systolic and diastolic mean determinated through ABPM</measure>
    <time_frame>after 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">187</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>valsartan/amlodipine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>losartan/amlodpine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valsartan/amlodpine</intervention_name>
    <description>tablets; 160mg/5mg; od; 4 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losartan/amlodpine</intervention_name>
    <description>tablets; 100mg/5mg; od; 4 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diastolic blood pressure in sitting position 100 to 109 mmHg and systolic blood
             pressure &gt; 140 mmHg at the end of the selection period

        Exclusion Criteria:

          -  type 2 diabetes mellitus

          -  heart failure

          -  AMI in the previous 6 months

          -  angina pectoris

          -  secondary hypertension

          -  malignant hypertension

          -  women child-bearing potential

          -  women who are pregnant and lactating

          -  suspected history of allergy to the sartans or calcium channels blockers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Fogari, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pavia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberto Fogari, MD</last_name>
    <phone>+39 0382 526217</phone>
    <email>r.fogari@unipv.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Giuseppe Derosa</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Derosa, MD</last_name>
      <phone>+39 0382 502614</phone>
      <email>giuseppe.derosa@unipv.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Derosa, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2008</study_first_submitted>
  <study_first_submitted_qc>July 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2008</study_first_posted>
  <last_update_submitted>July 16, 2008</last_update_submitted>
  <last_update_submitted_qc>July 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Roberto Fogari/Full Professor of Internal Medicine</name_title>
    <organization>University of Pavia</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Amlodipine, Valsartan Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

